Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Their lead candidate, DYNE-101, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback